AIM-listed Fulcrum Pharma takes on Knight as CFO

Fulcrum Pharma, a global drug development consultancy, has recruited Barry
Knight as its chief financial officer. He will take up the position immediately.

Knight was previously finance and administrative director of KeyMed, a
medical products provider, and qualified with Ernst & Young. Prior to that,
he was CFO of biotechnology company Trigen Ltd and Trigen Holdings, where he
gained merger and acquisition experience.

Graham Cook, chairman of Fulcrum Pharma, said: ‘Barry has a distinguished
career in finance and will bring substantial healthcare finance experience to
the management team and board of Fulcrum Pharma.’

Knight replaces Geoffrey Smith, who has held the top finance spot for almost
ten years and will stay until the end of June following a handover period.

Smith, who qualified with KPMG and specialised in corporate tax at Robson
Rhodes, has played a key role in listing the company on AIM. He worked on two
acquisitions and held the interim vice presidency of the US business while at
the company. Smith started his own tax practice in 1987 which he continues to
work for.

Frank Armstrong, chief executive of Fulcrum Pharma, said: ‘With the new
management team in place he [Smith] feels it is the right time to step down as
Fulcrum Pharma moves forward to the next stage of its growth and development.’

Further reading:

Accountant takes the helm at AG Barr

Related reading